Cargando…

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001()

The endogenous mediator of vasodilation, nitric oxide (NO), has been shown to be a potent radiosensitizer. However, the underlying mode of action for its role as a radiosensitizer – while not entirely understood – is believed to arise from increased tumor blood flow, effects on cellular respiration,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scicinski, Jan, Oronsky, Bryan, Ning, Shoucheng, Knox, Susan, Peehl, Donna, Kim, Michelle M., Langecker, Peter, Fanger, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529402/ https://www.ncbi.nlm.nih.gov/pubmed/26164533 http://dx.doi.org/10.1016/j.redox.2015.07.002

Ejemplares similares

RRx-001, A novel dinitroazetidine radiosensitizer
por: Oronsky, Bryan, et al.
Publicado: (2016)

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity
por: Zhao, Hongjuan, et al.
Publicado: (2015)

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
por: Ning, Shoucheng, et al.
Publicado: (2015)

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry
por: Zhao, Hongjuan, et al.
Publicado: (2017)

RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist
por: Oronsky, Bryan, et al.
Publicado: (2023)

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors
por: Oronsky, Bryan, et al.
Publicado: (2016)

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors
por: Raghunand, Natarajan, et al.
Publicado: (2017)

Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19
por: Oronsky, Bryan., et al.
Publicado: (2020)

Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment
por: Oronsky, Bryan, et al.
Publicado: (2014)

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients
por: Reid, T., et al.
Publicado: (2014)

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
por: Carter, Corey A., et al.
Publicado: (2015)

A Novel Hypoxia-Selective Epigenetic Agent RRx-001 Triggers Apoptosis and Overcomes Drug Resistance in Multiple Myeloma Cells
por: Das, Deepika Sharma, et al.
Publicado: (2016)

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria
por: Yalcin, Ozlem, et al.
Publicado: (2015)

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
por: Carter, Corey A., et al.
Publicado: (2016)

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001
por: Carter, Corey A., et al.
Publicado: (2016)

RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature
por: Jani, Vinay P., et al.
Publicado: (2021)

Rewriting the Epigenetic Code for Tumor Resensitization: A Review
por: Oronsky, Bryan, et al.
Publicado: (2014)

Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx‐001
por: Oronsky, Bryan, et al.
Publicado: (2018)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
por: Fine, Howard, et al.
Publicado: (2023)

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells
por: Oronsky, Bryan, et al.
Publicado: (2018)

The Implications of Hyponitroxia in Cancer
por: Oronsky, Bryan, et al.
Publicado: (2014)

Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats
por: Caroen, Scott, et al.
Publicado: (2022)

Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock
por: Brouse, Chad, et al.
Publicado: (2015)

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001
por: Oronsky, Bryan, et al.
Publicado: (2016)

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization
por: Carter, Corey A., et al.
Publicado: (2016)

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
por: Oronsky, Bryan, et al.
Publicado: (2020)

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)
por: Reid, Tony, et al.
Publicado: (2023)

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report
por: Brzezniak, Christina, et al.
Publicado: (2016)

RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice
por: Jurgensen, Kimberly J., et al.
Publicado: (2021)

The Capacity of Red Blood Cells to Reduce Nitrite Determines Nitric Oxide Generation under Hypoxic Conditions
por: Fens, Marcel H., et al.
Publicado: (2014)

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial()(): A TITE-CRM Phase I/II Clinical Trial
por: Kim, Michelle M., et al.
Publicado: (2016)

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
por: Cottrill, Hope, et al.
Publicado: (2018)

Complete metabolic response of metastatic castration‐resistant neuroendocrine carcinoma of the prostate after treatment with RRx‐001 and reintroduced platinum doublets
por: Ojemuyiwa, Michelle, et al.
Publicado: (2018)

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor
por: Brzezniak, Christina, et al.
Publicado: (2017)

Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001
por: Hammond, Terese Catherine, et al.
Publicado: (2022)

A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation
por: Jayabalan, Nanthini, et al.
Publicado: (2023)

Discovery and Clinical Evaluation of MK‐8150, A Novel Nitric Oxide Donor With a Unique Mechanism of Nitric Oxide Release
por: Knox, Clayton D., et al.
Publicado: (2016)

The multifaceted role of nitric oxide synthases in mitochondrial biogenesis and cell differentiation
por: Aquilano, Katia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3t7apsvgp6pmbcpbo88ummp2lj